Research progress in treatment of tuberculous meningitis
10.3760/cma.j.issn.1674-2397.2021.05.012
- VernacularTitle:结核性脑膜炎治疗研究进展
- Author:
Lele WANG
1
;
Jianqiong GUO
;
Jungang LI
;
Song YANG
;
Shenjie TANG
Author Information
1. 重庆市公共卫生医疗救治中心结核病研究室 400036
- Keywords:
Tuberculosis, meningeal;
Chemotherapy drugs;
Anti-inflammatory agent;
Interventional therapy;
Surgical treatment
- From:
Chinese Journal of Clinical Infectious Diseases
2021;14(5):392-398
- CountryChina
- Language:Chinese
-
Abstract:
Tuberculous meningitis is the most common and serious type of central nervous system tuberculosis, with high mortality and disability rate, which has attracted extensive attention of global public health. The high mortality rate and disability rate of tuberculosis meningitis may be related to its lack of specific clinical and imaging characteristics, insufficient attention from clinicians, lack of early sensitive and specific diagnostic testing techniques, delay in treatment, and restricted penetration of anti-TB drugs into the blood-brain barrier or/and MDR-TB, etc. This article reviews the disease burden of TBM, chemotherapy drugs and regimens, anti-inflammatory agents, aspirin, interventional and surgical treatment to provide reference for clinical management of this disease.
